Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year survival rate of merely 49.1%. The clinical management of HGSOC encounters substantial challenges, primaril...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2025-04-01
|
| Seri Bilgileri: | Frontiers in Immunology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1556377/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|